Company profile
Centralda Medical is a leading innovative medical device company in China, focusing on interventional medical devices in the field of drug-coated balloons (DCB) and thrombus aspiration catheters. At present, the company covers 24 products under research, of which two core DCB products, AcoArt Orchid & Dhalia and AcoArt TulipTM & Litos, have been approved by the State Drug Administration for the treatment of SFA/PPA lesions and BTK lesions, respectively.
Sino-Thai viewpoint
Two core products have been approved for commercialization, and future sales of AcoArt Orchid & Dhalia are expected to grow significantly: one of the company's core products, AcoArt Orchid & Dhalia, is a paclitaxel DCB designed to prevent stenosis or occlusion of the superficial femoral artery (SFA) and popliteal artery (PPA) and to treat arterial disease of the lower extremities (LEAD) with vascular intervention. According to Frost Sullivan, the number of LEAD patients in China is expected to reach 49.8 million by 2030. In the later stages of LEAD, such as severe and acute limb ischemia, revascularization must be performed through interventional surgery or bypass surgery to reduce the risk of amputation. China's related DCB product market is still in the early stage of development with great potential for growth. The number of knee DCB operations performed in China is expected to reach about 80, 000 in 2024, with a compound annual growth rate of 45.7 per cent from 2019 to 2024. In 2016, the company developed and launched China's first peripheral DCB product, about four years ahead of the second similar product, and in terms of revenue generated in 2020, the first peripheral DCB product dominates China's peripheral DCB market with a market share of about 86.9%. At present, three similar products have been approved by the State Drug Administration, namely, Reewarm PTX of Xinmai Medical Service (688016 CH), IN.PACT Admiral of Medtronic PLC (MDT US) and UltraFree of Guichuang Tongqiao (2190 HK). As AcoArtOrchid & Dhalia is the only laptop DCB product on the Chinese market for the treatment of SFA/PPA lesions in 2016-2019, sales of this product are expected to continue to grow in the future, benefiting from the company's first-mover advantage. The second core DCB product is designed to prevent stenosis or occlusion of subgenicular (BTK) arteries and to treat chronic limb ischemia with vascular intervention.
Approved by NMPA in December 2020, it became the first BTK DCB product in the world (the only one as of February 1, 2021) based on the results of multicenter randomized controlled clinical trials. The number of BTK DCB surgeries in China as a whole is expected to reach 150000 by 2030, with a compound annual growth rate of 23.9% from 2024 to 2030.